Prostate Cancer DNA Vaccine Results In Higher T-Cell Response When Delivered Via Inovio Biomedical’s Electroporation Delivery System
April 8th, 2008 Posted in prostate cancer preventionInovio Biomedical Corporation (AMEX:INO) will present interim data from a clinical study of an experimental DNA-based prostate cancer vaccine at the American Association for Cancer Research meeting in San Diego, USA, April 12 - 16, 2008.
The data indicates that the combination of this DNA vaccine and electroporation DNA delivery was safe and well-tolerated. Patients treated using electroporation also displayed higher levels of antibody and anti-DOM CD4 responses.
Tags: prostate cancer vaccine